A clinical study on pathological diagnosis and treatment target screening of head and neck malignant tumor based on high throughput genomics

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000036566

Enrollment

Unknown

Registered

2020-08-24

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head and neck malignant tumor

Interventions

Gold Standard:histopathological assessment

immunohistochemistry

Index test:high-throughput&#32

genomics&#32

sequencing

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Female or Male; Age: 18-70 years; Was willing and able to sign the informed consent; Was clinically diagnosed as head and neck malignant tumor; Underwent surgical treatment in the Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine;The surgical specimens were routinely sent to the Department of pathology for specimen collection and diagnosis.

Exclusion criteria

Exclusion criteria: Patients with insufficient tissues; subjects with poor predictive compliance or with other factors not suitable for this trial.

Design outcomes

Primary

Measure	Time frame
mutation;SEN, SPE, ACC, AUC of ROC;	—

Countries

China

Contacts

Public ContactJiang Li

Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

lijiang182000@126.com+86 13611791235

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026